# ACR-6840

Source: https://onco.cc/drugs/acr-6840/  
OnCo record `acr-6840` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ACR-6840 is an experimental small molecule from Acrivon Therapeutics, in preclinical development for cancer.

## Summary

ACR-6840 is a small molecule from Acrivon Therapeutics. An inhibitor of CDK11 from Acrivon's AP3-driven cell-cycle programme. Its furthest stage is preclinical development, for cancer. No clinical trial naming it is registered on ClinicalTrials.gov. IND-enabling studies; IND filing for ACR-6840 'or alternative CDK11 inhibitor candidate' planned for the first half of 2027 (Q1 2026 results release, 13 May 2026). The 12 August 2026 release no longer names ACR-6840 and refers to an 'Internally-discovered development candidate'. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: ACR-6840
- Modality: Small molecule
- Mechanism: An inhibitor of CDK11 from Acrivon's AP3-driven cell-cycle programme.

## Sources

- Acrivon Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1781174/000119312526221626/acrv-ex99_1.htm
- Acrivon Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1781174/000119312526221626/acrv-ex99_1.htm
- Acrivon Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/acrv-ex99_1.htm

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [CDK11](https://onco.cc/targets/cdk11/)
- companies: [Acrivon Therapeutics](https://onco.cc/companies/acrivon-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/acr-6840.json